Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2937 | ZT-12-037-01 | Specific STK19 inhibitor | €95.00 | |
| 1839 | Zosuquidar trihydrochloride | Inhibitor of P-glycoprotein | €95.00 | |
| 4142 | Z29077885 hydrochloride | Potent STK33 inhibitor; Antiviral agent | Recently added | €120.00 |
| 4239 | Z29077885 | Potent STK33 inhibitor; Antiviral agent | Recently added | €120.00 |
| 2385 | WZ 4003 | Specific dual inhibitor of NUAK1 (ARK5) and NUAK2 (SNARK) | €80.00 | |
| 3068 | WEHI-9625 | First-in-class, potent, and selective mBAK-mediated apoptosis inhibitor | €150.00 | |
| 2628 | TMS | CYP1B1 inhibitor that induces apoptosis in human cancer cells | €75.00 | |
| 1960 | Tariquidar | Inhibitor of P-glycoprotein (P-gp, ABCB1) | €135.00 | |
| 2124 | TAK 700 | Potent and highly selective inhibitor of 17,20-lyase (CYP17A1) | €105.00 | |
| 1136 | SU 6656 | SRC kinase inhibitor | €120.00 | |
| 2743 | STK16-IN-1 | ATP-competitive STK16 inhibitor | €125.00 | |
| 1865 | Stemregenin 1 | Aryl hydrocarbon receptor (AHR) antagonist | €105.00 | |
| 2778 | Squarunkin A | Selective UNC119–cargo interaction inhibitor | €125.00 | |
| 1701 | Shz-1 | Stem cell differentiating agent; Nkx2.5 inducer | €95.00 | |
| 3284 | Saracatinib | Inhibitor of SRC and ABL tyrosine kinases | €70.00 | |
| 3723 | S63845 | BH3-Groove binding Mcl-1 inhibitor | Inquire | |
| 3222 | Reversan | Potent, selective and non-toxic MRP1 inhibitor | €90.00 | |
| 3269 | PSB-KD107 | Selective agonist for GPR18 | €140.00 | |
| 1871 | Pifithrin-α hydrobromide | Inhibitor of p53 protein | €95.00 | |
| 3784 | PGP-4008 | Selective P-glycoprotein (Pgp) inhibitor | €120.00 | |
| 2600 | PF 06463922 | Potent, orally available and brain-penetrant ALK/ROS1 selective inhibitor | €105.00 | |
| 2026 | PF 04981517 | Inhibitor of Cytochrome P450 3A4 (CYP3A4) | €150.00 | |
| 4083 | PDS0330 | Potent and selective first-generation claudin-1 inhibitor | Recently added | €140.00 |
| 3614 | Parthenolide | NF-κB activation inhibitor | €90.00 | |
| 4152 | Obatoclax | B-cell lymphoma-2 (BCL-2) inhibitor | Inquire | |
| 1416 | NVP-TAE684 | NPM-ALK inhibitor | €50.00 | |
| 3277 | NSC194598 | p53 DNA-binding inhibitor | €130.00 | |
| 3079 | NPB | Potent, site-specific Bcl-2-associated death promoter (BAD) inhibitor | €130.00 | |
| 3387 | NF-κB Activation Inhibitor IV | Potent NF-κB activation inhibitor | €90.00 | |
| 1941 | MLR 1023 | Selective allosteric activator of Lyn kinase | €95.00 | |